In a significant development within Alzheimer’s research, new drugs targeting amyloid proteins have come under intense scrutiny following a comprehensive review by Cochrane, a leading authority in medical evidence evaluation. The review, which critically examined the efficacy of these biological drugs, found that they fail to provide substantial clinical benefits while posing high financial costs and a risk of severe side effects. In light of these findings, a Czech-based company, H2 Global Group, has proposed an alternative treatment using molecular hydrogen, presenting this solution to the governments of all 27 European Union member states.
On April 16, 2026, Cochrane released a systematic analysis of anti-amyloid monoclonal antibodies used in patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease. This detailed assessment, which incorporated data from 17 clinical trials with over 20,000 participants, concluded that the impact of these drugs is minimal, lacking the significant clinical benefits initially hoped for. Furthermore, the review pointed out an increased occurrence of adverse effects such as brain swelling and microhemorrhages. The lead author, Francesco Nonino from the IRCCS Institute of Neurological Sciences in Bologna, emphasized the need for future Alzheimer’s research to explore alternative treatment pathways beyond the amyloid hypothesis.
The findings have sparked widespread reaction from global media and experts. Publications like The Guardian and Scientific American described the effect of the drugs as “trivial,” while The New York Times highlighted the ongoing debate about their clinical value. Meanwhile, experts such as Professor Robert Howard from University College London commented on the over-optimistic portrayal of these drugs to patients’ families, and Professor Paresh Malhotra from Imperial College London suggested that research should broaden its focus beyond amyloid-targeting strategies. With the annual treatment cost estimated at around €77,000 ($82,000 USD) per patient, these drugs have faced reimbursement challenges in several European countries.
In response to these challenges, H2 Global Group has put forward a novel treatment approach combining molecular hydrogen therapy with virtual reality cognitive rehabilitation. This method, developed in collaboration with a VR company whose solution is already used in over 40 European hospitals, addresses oxidative stress, neuroinflammation, and neurodegeneration. The company holds a patent for a dementia treatment that includes the use of gaseous hydrogen, even in cases where conventional treatments have failed. This strategy is grounded in research by Professor Shigeo Ohta of Nippon Medical School, whose studies have demonstrated hydrogen’s therapeutic antioxidant effects.
David Maršálek, CEO of H2 Global Group, expressed optimism about the potential of Czech innovation to lead a transformative solution for Alzheimer’s treatment. He emphasized the opportunity for the Czech Republic to spearhead a large-scale clinical study in collaboration with EU nations, aiming to provide a safe and effective treatment for millions of patients. With a regulator-approved clinical study already underway, Maršálek urged for immediate action to capitalize on this promising intersection of Czech and Japanese technological advances in combating the global dementia epidemic.